Company news
Fulcrum Therapeutics, Inc. news in 2026
Fulcrum Therapeutics, Inc.'s news releases, calls and decks from 2026, newest first.
Fulcrum Therapeutics and Slate Medicines Announce Merger Agreement to Advance Next-Generation Migraine Therapies
August 17, 2026
Fulcrum Therapeutics Announces Discontinuation of Pociredir Program in Sickle Cell Disease and Initiation of Strategic Review
June 1, 2026
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2026
April 27, 2026
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
April 27, 2026
Fulcrum Therapeutics to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, April 27, 2026, at 8: 00 a.m. ET
April 20, 2026
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
March 19, 2026
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2025
February 24, 2026
Fulcrum Therapeutics Announces Positive 12-Week Results from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
February 23, 2026
Fulcrum Therapeutics to Present 12-Week Data from the 20 mg Dose Cohort of the Phase 1b PIONEER Trial of Pociredir in Sickle Cell Disease
February 17, 2026
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 9, 2026
Fulcrum Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
January 6, 2026
Calls in 2026
Decks in 2026
- Merger or Acquisition (August 2026)
Merger or acquisition · 26 slides · Aug 17, 2026
- Investor Presentation (January 2026)
Investor deck · 28 slides · Jan 12, 2026